“…To the best of our knowledge, FI investigation for HCC trials has not been performed. The FI has been evaluated in other RCTs, such as emergency medicine [11], giant cell arteritis, Clinical Practice Guidelines [12], and cardiac surgery field [13]. These studies consistently show that many RCTs are fragile, and several researchers have recommended that FI should be adopted in reporting clinical trial outcomes [12,14], our study showed that most results from the randomized trials were far more fragile.…”